KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $201.3 million.

  • Amneal Pharmaceuticals' Operating Expenses rose 1186.31% to $201.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.9 million, marking a year-over-year increase of 1179.63%. This contributed to the annual value of $669.5 million for FY2024, which is 1245.12% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Operating Expenses stood at $201.3 million, which was up 1186.31% from $173.3 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Operating Expenses registered a high of $201.3 million during Q3 2025, and its lowest value of $139.0 million during Q2 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' median Operating Expenses value was $152.7 million (recorded in 2024), while the average stood at $156.3 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Operating Expenses soared by 1964.55% in 2021, and later tumbled by 782.3% in 2022.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Operating Expenses stood at $156.4 million in 2021, then decreased by 7.82% to $144.2 million in 2022, then increased by 7.65% to $155.2 million in 2023, then grew by 18.2% to $183.4 million in 2024, then grew by 9.74% to $201.3 million in 2025.
  • Its Operating Expenses stands at $201.3 million for Q3 2025, versus $173.3 million for Q2 2025 and $158.9 million for Q1 2025.